DVC1 0101

Drug Profile

DVC1 0101

Alternative Names: Angiogenic-gene-therapy-ID-Pharma; DVC1-0101; Fibroblast growth factor 2 gene therapy - ID Pharma; SeV-10101; SEV1-0101

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DNAVEC Corporation
  • Developer ID Pharma; Kyushu University
  • Class Gene therapies; Nucleic acids
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor expression modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Intermittent claudication; Peripheral ischaemia

Most Recent Events

  • 22 Nov 2016 Phase-I/II clinical trials in Intermittent claudication in Australia (IM) (ACTRN12615001144505)
  • 22 Nov 2016 Phase-I/II clinical trials in Peripheral ischaemia in Australia (IM) (ACTRN12615001144505)
  • 08 Jun 2016 ID Pharma plans a phase I/IIa trial for Intermittent claudication and Peripheral ischaemia in Australia (IM) (ACTRN12615001144505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top